Today is #WorldLungCancerDay, a day focused on raising awareness of the challenges of #lungcancer - which accounts for nearly 1/5 cancer deaths globally. At Inivata, we show our support for all those impacted and remain committed to helping transform care for cancer #patients.

ICYMI, we shared a poster presentation on “Plasma first: Accelerating lung #cancer diagnosis through liquid biopsy” at the 2022 ASCO® Annual Meeting. See here: inivata.com/wp-content/upl… #ASCO22

At Inivata, our purpose is to help guide more informed #treatments for cancer patients. To hear the story of the first #patient tested with our InVisionFirst-Lung #liquidbiopsy test for #NSCLC, please see below. vimeo.com/699410987

Great to see in The ICR, alongside many other key stakeholders, supporting the use of biomarker testing to improve cancer patient diagnosis & care. Read more in this article from The Times and The Sunday Times: bit.ly/3p3fbuk #diagnostics #oncology #liquidbiopsy

The ESMO - Eur. Oncology Annual Meeting takes place next month. Members of #TeamInivata will be on the ground in Paris. For meetings, please contact Vishal Sikri, David Eberhard, Mike Nahorski, Huw Ricketts and Chris Pipinikas. esmo.org/meetings/esmo-… #ESMO22

This September, Inivata is once again supporting #GynecologicCancerAwarenessMonth. Join us in highlighting the importance of bringing awareness to all gynecologic cancers. Get involved here: foundationforwomenscancer.org/events-courses…

#TeamInivata, alongside its collaborators, will present new #data on our #RaDaR™ assay for the detection of #MRD and recurrence at the ESMO - Eur. Oncology Congress, taking place between 9-13 September 2022. Read more here: bit.ly/3RDLtsF #ESMO22

Our CMO, David Eberhard, recently spoke with @GENBio about the challenges of detecting #MRD and how #liquidbiopsies can address these. Click below to read more about how we are working to transform care for cancer patients. bit.ly/3Bc9dgv #drugdevelopment #oncology

The ESMO - Eur. Oncology congress kicks off tomorrow. For meetings, please contact Vishal Sikri, David Eberhard, Mike Nahorski, Huw Ricketts or Chris Pipinikas or get in touch at: inivata.com/about-us/conta… #ESMO22

Don’t miss our RaDaR #data being shared on Sunday at #ESMO22. #TeamInivata and collaborators will be presenting a poster titled ‘Liquid biopsy for detection of molecular residual disease and recurrence in head and neck squamous cell carcinoma’ at 2-3pm CEST. ESMO - Eur. Oncology

Later today, #TeamInivata and collaborators will be presenting a poster, titled ‘Updated follow-up data and biomarker analysis of pre-operative ipilimumab and nivolumab in locoregional advanced urothelial cancer (NABUCCO)’ at 3-4pm CEST at #ESMO22. ESMO - Eur. Oncology

#TeamInivata and its collaborators’ poster titled ‘Updated follow-up data and biomarker analysis of pre-operative ipilimumab and nivolumab in locoregional advanced urothelial cancer (NABUCCO) won best poster in the session today at #ESMO22. ESMO - Eur. Oncology

We will be attending the 12th Annual World Clinical Biomarkers & CDx Summit, taking place from 26-29 September in Boston. Our colleagues at NeoGenomics will also be delivering a #presentation entitled ‘From Bench to Bedside: A CDx Odyssey’. world-cdx.com #event

ICYMI #TeamInivata and collaborators presented a poster on ‘Liquid biopsy for detection of molecular residual disease and recurrence in head and neck squamous cell carcinoma’ at #ESMO22. View here: inivata.com/wp-content/upl… ESMO - Eur. Oncology #data #presentation

Come and meet #TeamInivata at this year’s 12th Annual World Clinical Biomarkers & #CDx Summit, taking place from 26-29 September. Find out more here: world-cdx.com #drugdevelopment #diagnostics #oncology

ICYMI #TeamInivata and collaborators presented ‘Updated follow-up data and biomarker analysis of pre-operative ipilimumab and nivolumab in locoregional advanced urothelial cancer (NABUCCO)’ at #ESMO22. View here: inivata.com/wp-content/upl… ESMO - Eur. Oncology #MRD #data